Combining multiple cell death pathway-related risk scores to develop neuroblastoma cell death signature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combining multiple cell death pathway-related risk scores to develop neuroblastoma cell death signature

Published:2023-02-13 Issue:9 Volume:149 Page:6513-6526
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Han Yahui,Li Biyun,Yan Dun,Zhou Diming,Yuan Xiafei,Zhao Wei,Zhang Da,Zhang Jiao

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-04605-5.pdf

Reference35 articles.

1. Andrews LP, Marciscano AE, Drake CG, Vignali DA (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276(1):80–96. https://doi.org/10.1111/imr.12519

2. Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S (2017) Management of neuroblastoma: ICMR consensus document. Indian J Pediatr 84(6):446–455. https://doi.org/10.1007/s12098-017-2298-0

3. Blanche P, Dartigues JF, Jacqmin-Gadda H (2013) Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med 32(30):5381–5397. https://doi.org/10.1002/sim.5958

4. Chen X, Zeh HJ, Kang R, Kroemer G, Tang D (2021) Cell death in pancreatic cancer: from pathogenesis to therapy. Nat Rev Gastroenterol Hepatol 18(11):804–823. https://doi.org/10.1038/s41575-021-00486-6

5. Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):1–11. https://doi.org/10.1038/s12276-018-0191-1

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atherosclerotic plaque vulnerability quantification system for clinical and biological interpretability;iScience;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3